Complications of Type 2 Diabetes on the Decline: Which Ones and by How Much?

Your daily dose of clinical news you may have missed.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Sanofi is the third key insulin maker to announce reductions in the cost of its products, joining other giants Eli Lilly and Co and Novo Nordisk.

The patient, an active 49-year-old man, had an HbA1c of 8.6 after diabetes was first diagnosed. It’s now 7.6 with metformin and lifestyle measures. Is the current A1c goal adequate, or should you treat more aggressively?

Young children using a hybrid closed-loop insulin delivery system spent 12% more time within their target blood glucose range than those who received standard care, according to new research.

Each of the quotes is taken from a study reviewed on Patient Care during the week and was chosen for the research team’s passion about the clinical implications of their findings.